Antisense modulation of insulin-like growth factor 2 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsSanjay Bhanot, Kenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of insulin-like growth factor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding insulin-like growth factor 2. Methods of using these compounds for modulation of insulin-like growth factor 2 expression and for treatment of diseases associated with expression of insulin-like growth factor 2 are provided.
Claims20
A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding insulin-like growth factor 2, wherein said compound specifically hybridizes with said nucleic acid molecule encoding insulin-like growth factor 2 and inhibits the expression of insulin-like growth factor 2.
A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding insulin-like growth factor 2.
A method of screening for an antisense compound, the method comprising the steps of:
- a. contacting a preferred target region of a nucleic acid molecule encoding insulin-like growth factor 2 with one or more candidate antisense compounds, said candidate antisense compounds comprising at least an 8-nucleobase portion which is complementary to said preferred target region, and
- b. selecting for one or more candidate antisense compounds which inhibit the expression of a nucleic acid molecule encoding insulin-like growth factor 2.
Dependencies are inferred from the claim text.